The Quiet Chip Tester With AI Dreams and EV Scars

This stock has been left for dead by the EV slowdown, but the AI hardware boom might be handing it a second life.

The market still doubts the story, yet the backlog is climbing, and management keeps hinting at a turnaround in the making.

Urgent Warning (Sponsored)

Porter Stansberry: This Could Be Bigger Than A Stock Crash or Financial Collapse

A brutal, invisible new force is about to rip America apart… and the resulting civil unrest, political chaos, and cries for radical change will be immense.

Unlike any we’ve seen in living memory. 

And unless you prepare now you could see your wealth decimated in the years ahead.

I shared everything you need to know about what’s coming next in my new exposé. 

Click here to watch it for free. 

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Confluent | CFLT

Price: $30.53

The data streaming world got a jolt this month when IBM announced a deal to acquire Confluent for $31 per share, valuing the company at about $11 billion.

The logic is simple: if AI runs on data, someone has to move and clean that data first—and that’s Confluent’s lane.

Its Kafka-based platform makes data portable, real-time, and usable across an enterprise, an essential step before AI tools can even get started.

For investors, this is the end of one story and the start of another.

The near-term upside is capped at the buyout price, but IBM’s willingness to pay a premium validates the long-term thesis that real-time data streaming is now critical infrastructure.

The next question will be whether regulators or integration challenges slow the process, but in terms of strategic fit, it’s as natural as it gets.

Why it matters for you: CFLT shows how valuable plumbing companies can be when the AI economy scales. It may not be glamorous, but it’s essential, and that’s where long-term money often wins.

BILL Holdings | BILL

Price: $46.60

BILL has been on a long slide from its pandemic highs, but that’s made the math interesting again.

The fintech company helps small businesses manage payables, receivables, and cash flow digitally—basically automating what used to take a stack of invoices and a shoebox of receipts.

Growth slowed sharply as small-business formation cooled and rate pressure squeezed margins, but BILL’s fundamentals are far from broken.

Discounted cash flow models now point to intrinsic values near $90 per share, roughly 40% above current levels.

That’s not a guarantee of a rebound, but it shows the stock has moved from priced-for-perfection to priced-for-pessimism. 

With small-business spending stabilizing and inflation pressures easing, even modest reacceleration in payments volume could lift sentiment fast.

Why it matters for you: BILL is a recovery setup. It’s not a high-growth fintech anymore, but if cash flow keeps improving, valuation alone could spark a rerating.

Gold’s Hidden Opportunity (Sponsored)

Can gold pull off a repeat in 2026?

Gold capped off one of the biggest rallies in modern history, but is there more upside ahead?

According to Dr. David Eifrig, a former Goldman Sachs VP, gold’s next move could be even bigger than last year’s.

Major banks like JPMorgan and Goldman Sachs predict gold will rise to $5,000 per ounce, but Dr. Eifrig believes a secret Washington plan could push it even higher.

He's urging investors to position themselves now by moving into his top gold stock, with 1,000% upside potential.

[Get the Full Details Here]

*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.

Upstart | UPST

Price: $48.12

Upstart is a rare case where AI has been part of the business model since day one.

The company uses machine learning to assess credit risk, aiming to approve borrowers traditional models might miss. 

It’s a smart idea, but one that got punished hard when rates surged and credit appetite dried up. Now, investors are watching for signs that lending volume and funding stability are finally turning a corner.

Earnings expectations have rebounded sharply, with analysts forecasting EPS up nearly 80% year over year and revenue up more than 30%.

The big test is whether these results show lasting improvement or just a short-term recovery fueled by macro tailwinds. 

If Upstart can demonstrate consistent loan performance and funding diversity, it might finally break out of the “flash-in-the-pan fintech” bucket it’s been stuck in.

Why it matters for you: UPST is still high beta, but if its AI credit models prove durable through a full rate cycle, it could graduate from speculative to sustainable growth.

Inspire Medical Systems | INSP

Price: $92.20

Inspire Medical sits in a very different corner of innovation, treating sleep apnea with implantable neurostimulation rather than bulky CPAP devices. 

The newest generation, Inspire V, is rolling out faster than expected, with better surgical efficiency and improved outcomes.

Strong clinical adoption and expanded reimbursement coverage suggest the fundamentals are intact, even if the stock has been bruised.

The main challenges now are timing and execution.

The transition from Inspire IV to V has created some temporary inventory and reporting noise, while GLP-1 drugs (used for weight loss) are pulling some attention away from traditional sleep apnea treatment. 

But over the long run, the patient funnel is still expanding, and Inspire’s economics look more favorable as reimbursement rates rise and surgeons become more productive.

Why it matters for you: INSP is a niche medtech name with real competitive advantages. Once the product transition normalizes, it could start reclaiming lost ground quickly.

Aehr Test Systems | AEHR

Price: $28.81

Aehr has been on a roller coaster, swinging from EV darling to AI wildcard.

The company’s bread and butter is wafer-level burn-in testing—a process used to stress-test semiconductors before they’re packaged.

That made it a major beneficiary of the EV and SiC chip boom. Then EV orders cooled, revenue dipped, and the market walked away.

Now the next wave may be forming around AI chips.

Aehr’s recent bookings include new orders from a “world-leading hyperscaler” for testing AI processors, and its backlog has climbed from $11.8 million to $18.3 million in just a few months. 

Management expects $60–80 million in second-half bookings, which could reset growth expectations for fiscal 2027.

It’s still a small-cap and still volatile, but the setup looks like a genuine second act.

Why it matters for you: AEHR sits at the crossroads of two massive semiconductor trends—EVs and AI.

If it executes on AI chip testing while EV demand rebounds, the current valuation could look like a bargain.

📊 Stat of the Day: $29.4 Billion

The U.S. trade deficit fell to $29.4 billion in October, the lowest monthly level since 2009. Imports dropped while exports rose, shrinking the imbalance by nearly 40% month over month.

It’s a reminder that even in a noisy macro year, some old-fashioned indicators are flashing signs of cooling demand.